Supernus Pharmaceuticals Inc (SUPN) Shares Bought by Public Employees Retirement Association of Colorado

Share on StockTwits

Public Employees Retirement Association of Colorado lifted its position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 64.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,732 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,019 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Supernus Pharmaceuticals were worth $389,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SevenBridge Financial Group LLC acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $113,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $203,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $204,000. Everence Capital Management Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $205,000. Finally, Cim LLC acquired a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $207,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Shares of SUPN stock opened at $47.41 on Wednesday. The stock has a market capitalization of $2.47 billion, a P/E ratio of 37.63 and a beta of 0.79. Supernus Pharmaceuticals Inc has a 52-week low of $33.30 and a 52-week high of $61.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.54 and a current ratio of 2.74.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.14. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. The firm had revenue of $99.54 million for the quarter, compared to analysts’ expectations of $101.01 million. As a group, equities research analysts forecast that Supernus Pharmaceuticals Inc will post 1.93 EPS for the current fiscal year.

SUPN has been the topic of a number of research analyst reports. BidaskClub cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 6th. Piper Jaffray Companies set a $47.00 price target on Supernus Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, July 8th. Zacks Investment Research cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 1st. Cantor Fitzgerald set a $56.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 8th. Finally, Jefferies Financial Group boosted their price target on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $55.30.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Read More: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply